Navigation Links
Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
Date:10/13/2008

NATICK, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th news release, a significant portion of this trading was due to involuntary sales of shares beneficially owned by Boston Scientific's co-founders Pete Nicholas and John Abele. As of the close of the market on Friday, approximately 31 million shares in aggregate had been sold last week through involuntary sales related to collateralized loans of Mr. Nicholas and Mr. Abele, including nearly 13 million shares on Friday.

The Company believes there may be additional involuntary sales of shares beneficially owned by Mr. Nicholas and Mr. Abele over the next several weeks, but the Company estimates, based upon an assessment of the facts available to it and the price of the Company's stock at the close of business on Friday, October 10th, that the majority of the involuntary selling has already occurred.

"While these involuntary sales are certainly disappointing, it is important to keep in mind that the Company has approximately 1.5 billion shares outstanding and that even after the events of last week John Abele and I continue to collectively hold more than 90 million shares of Boston Scientific stock," said Nicholas. "Our confidence in the Company and its future is unwavering."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding potential additional automatic selling and our long-term prospects. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... PHOENIX and SAN DIEGO ... (OTCQB:CELZ) announced the appointment of Santosh Kesari , ... Board. Dr. Kesari will leverage his experience in neurology and ... its adult stem cell for treatment of stroke. The AmnioStem ... amniotic fluid, which has previously shown therapeutic activity in ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) inhibited the direct neurotoxic effect of prion-like forms of Amyloid ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... report "Biomarkers - Technologies, Markets and Companies" to their ... , , ... biomarkers and their discovery using various -omics technologies such as proteomics ... biomarkers and new tests are also based on biomarker. ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
Breaking Biology Technology:
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
Breaking Biology News(10 mins):